Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation
1. FDA accepted Achieve's NDA for smoking cessation treatment. 2. PDUFA action date set for June 20, 2026. 3. Cytisinicline shows significant effectiveness in Phase 3 trials. 4. Over 2,000 participants contributed to supporting data. 5. Cytisinicline targets a high-need public health issue.